Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, alleging that the company made materially false and misleading statements regarding its business and operations [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Telix's defendants overstated the progress made with prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. - Investors are entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by January 9, 2026, to represent other class members in the litigation [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].
ROSEN, LEADING INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX